Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine

F. Villamil, G. Levy, G. L. Grazi, S. Mies, D. Samuel, F. Sanjuan, M. Rossi, J. Lake, S. Munn, F. Mühlbacher, L. Leonardi, U. Cillo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72%) and 24 of 29 given tacrolimus (83%) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87%) cyclosporine-treated patients and 37 of 37 (100%) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66% with cyclosporine and 90% with tacrolimus; for fibrosis stage 3 or 4 it was 46% and 80%, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.

Original languageEnglish
Pages (from-to)2964-2967
Number of pages4
JournalTransplantation Proceedings
Volume38
Issue number9
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Tacrolimus
Cyclosporine
Transplants
Hepacivirus
Liver
Infection
Recurrence
Fibrosis
Graft Survival
Virus Diseases
Chi-Square Distribution
Liver Transplantation
Hepatitis
Observational Studies
Antiviral Agents
Biopsy

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine. / Villamil, F.; Levy, G.; Grazi, G. L.; Mies, S.; Samuel, D.; Sanjuan, F.; Rossi, M.; Lake, J.; Munn, S.; Mühlbacher, F.; Leonardi, L.; Cillo, U.

In: Transplantation Proceedings, Vol. 38, No. 9, 11.2006, p. 2964-2967.

Research output: Contribution to journalArticle

Villamil, F, Levy, G, Grazi, GL, Mies, S, Samuel, D, Sanjuan, F, Rossi, M, Lake, J, Munn, S, Mühlbacher, F, Leonardi, L & Cillo, U 2006, 'Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine', Transplantation Proceedings, vol. 38, no. 9, pp. 2964-2967. https://doi.org/10.1016/j.transproceed.2006.08.131
Villamil, F. ; Levy, G. ; Grazi, G. L. ; Mies, S. ; Samuel, D. ; Sanjuan, F. ; Rossi, M. ; Lake, J. ; Munn, S. ; Mühlbacher, F. ; Leonardi, L. ; Cillo, U. / Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 9. pp. 2964-2967.
@article{bc75fd6033cc4e9f9df14684dfda16ee,
title = "Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine",
abstract = "Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72{\%}) and 24 of 29 given tacrolimus (83{\%}) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87{\%}) cyclosporine-treated patients and 37 of 37 (100{\%}) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66{\%} with cyclosporine and 90{\%} with tacrolimus; for fibrosis stage 3 or 4 it was 46{\%} and 80{\%}, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.",
author = "F. Villamil and G. Levy and Grazi, {G. L.} and S. Mies and D. Samuel and F. Sanjuan and M. Rossi and J. Lake and S. Munn and F. M{\"u}hlbacher and L. Leonardi and U. Cillo",
year = "2006",
month = "11",
doi = "10.1016/j.transproceed.2006.08.131",
language = "English",
volume = "38",
pages = "2964--2967",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine

AU - Villamil, F.

AU - Levy, G.

AU - Grazi, G. L.

AU - Mies, S.

AU - Samuel, D.

AU - Sanjuan, F.

AU - Rossi, M.

AU - Lake, J.

AU - Munn, S.

AU - Mühlbacher, F.

AU - Leonardi, L.

AU - Cillo, U.

PY - 2006/11

Y1 - 2006/11

N2 - Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72%) and 24 of 29 given tacrolimus (83%) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87%) cyclosporine-treated patients and 37 of 37 (100%) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66% with cyclosporine and 90% with tacrolimus; for fibrosis stage 3 or 4 it was 46% and 80%, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.

AB - Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72%) and 24 of 29 given tacrolimus (83%) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87%) cyclosporine-treated patients and 37 of 37 (100%) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66% with cyclosporine and 90% with tacrolimus; for fibrosis stage 3 or 4 it was 46% and 80%, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.

UR - http://www.scopus.com/inward/record.url?scp=33750952074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750952074&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.08.131

DO - 10.1016/j.transproceed.2006.08.131

M3 - Article

C2 - 17112875

AN - SCOPUS:33750952074

VL - 38

SP - 2964

EP - 2967

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 9

ER -